Delineating the mechanistic relevance of the TP53 gene and its mutational impact on gene expression and patients’ survival in bladder cancer

• Published in: Heliyon Vol. 10; no. 10; p. e31286
• Main Authors: Chatterjee, Dipankor, Heeamoni, Shabiha Afroj, Sultana, Tamanna, Mou, Sadia Islam, Mostofa, Munshi Akid, Hossain, Md Akmal, Hosen, Md Ismail, Faruk, Md Omar
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 30.05.2024; Elsevier
• Subjects: Bladder carcinoma; Diagnosis; Overall survival; Somatic mutation; Tumor suppressor; Somatic mutation; Diagnosis; Bladder carcinoma; Overall survival; Tumor suppressor
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e31286

Bladder carcinoma (BLCA) is a widespread urological malignancy causing significant global mortality, often hindered by delayed diagnosis and limited treatments. BLCA frequently exhibits TP53 mutations, playing a pivotal role in its pathogenesis and underscoring the potential of targeting TP53 as a therapeutic approach for this prevalent urological malignancy. Tumor tissues from 50 bladder cancer patients were used for mutational analysis in TP53's mutation-rich exons (5, 7, & 8). The gene expression of the TP53 gene, along with a TP53-target gene B‐cell translocation gene 2 (BTG2) was also assessed in the cDNA samples from the same BLCA tissues and 15 urine controls of healthy people. The analysis revealed 22 % of patients with somatic hotspot mutations, 18 % with pathogenic missense mutations, and 12 % with intronic variants. Patients with somatic mutations exhibited the worst prognosis, supported by survival analysis from The Cancer Genome Atlas (TCGA) BLCA data. Interestingly, H296Y missense mutation correlated with higher TP53 expression and improved survival, while intronic SNPs were linked to worse outcomes. Additionally, upregulated BTG2 expression in mutated patients was observed which was correlated with poor prognosis, emphasizing the role of TP53 mutations in bladder cancer progression. The multivariate analysis highlighted the predictive power of TP53 mutations, with a high frequency of high-grade tumors (78.57 %) in mutated patients, underscoring their role in cancer progression. In conclusion, this study emphasizes the crucial role of TP53 mutations in bladder cancer patients from Bangladesh. •46 % of the Bangladeshi bladder cancer cohort carried TP53 mutations.•TP53-mutated patients showed altered target gene expression in BLCA.•TP53-mutated BLCA patients are associated with poor survival.•TCGA bladder cancer dataset analysis validated each observation.